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Abstract
Background: PPARγ is an isoform of peroxisome proliferator-activated receptor (PPAR) belonging to a super family
of nuclear receptors. PPARγ receptor is found to play a crucial role in the modulation of lipid and glucose
homeostasis. Its commotion has been reported to play a significant role in a broad spectrum of diseases such as
type 2 diabetes mellitus, inflammatory diseases, Alzheimer’s disease, and in some cancers. Hence, PPARγ is an
important therapeutic target. Polyunsaturated fatty acids (PUFAs) and their metabolites (henceforth referred to as
bioactive lipids) are known to function as agonists of PPARγ. However, agonistic binding modes and affinity of
these ligands to PPARγ are yet to be deciphered.
Methods: In this study, we performed a comparative molecular docking, binding free energy calculation and
molecular dynamics simulation to infer and rank bioactive lipids based on the binding affinities with the ligand
binding domain (LBD) of PPARγ.
Results: The results inferred affinity in the order of resolvin E1 > neuroprotectin D1 > hydroxy-linoleic acid >
docosahexaenoic acid > lipoxin A4 > gamma-linolenic acid, arachidonic acid > alpha-linolenic acid > eicosapentaenoic
acid > linoleic acid. Of all the bioactive lipids studied, resolvin E1, neuroprotectin D1 and hydroxy-linoleic acid showed
significant affinity comparable to proven PPARγ agonist namely, rosiglitazone, in terms of Glide XP docking score, H-bond
formation with the key residues, binding free energy and stable complex formation with LBD favouring co-activator
binding, as inferred through Molecular Dynamics trajectory analysis.
Conclusion: Hence, these three bioactive lipids (resolvin E1, neuroprotectin D1 and hydroxy-linoleic acid) may be
favourably considered as ideal drug candidates in therapeutic modulation of clinical conditions such as type 2 DM,
Alzheimer’s disease and other instances where PPARγ is a key player.
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Background
Peroxisome proliferator-activated receptor (PPAR) com-
prises of three isoforms, α, β and γ belonging to a super
family of nuclear receptors [1]. PPARs are ligand- acti-
vated transcription factors that regulate genes playing a
vital role over a broad spectrum of physiological and
pathological conditions [2]. PPAR receptors are
expressed by various tissues including muscles, hepato-
cytes, adipocytes and endothelial cells. Though the three
isoforms of PPAR (α, β and γ) share high level of se-
quence and structural similarity they are distinct in
terms of expression and tissue distribution [3]. Molecu-
lar 3D structure of PPAR constitutes DNA binding do-
main at the N-terminus and ligand binding domain
(LBD) at the C-terminus. PPAR’s interaction with its
agonist leads to heterodimer formation with retinoid X
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receptor (RXR) [4]. PPAR-RXR heterodimer gets
bounded at peroxisome proliferator response elements
(PPREs) occupying the promoter region of target specific
genes. Further, this process leads to recruitment of vari-
ous transcriptional cofactors involved in the initiation of
transcription process, thereby, triggering expression of
several genes involved in diverse physiological and
pathological processes [5–7]. Each PPAR subtype plays a
unique physiological role in different tissues; however,
all the three isoforms are well known to be involved in
lipid and glucose homeostasis [8]. Of all the three iso-
forms, PPAR α and γ are most extensively studied when
compared to PPAR β.
PPARα is predominantly expressed in tissues involved
in metabolic activities of various tissues including mus-
cles, heart, liver, intestine and brown adipose cells.
PPARα activation leads to a decrease in lipid levels.
PPARα receptor functions as a lipid sensor and helps in
controlling energy combustion [9–12]. PPARγ is widely
expressed in adipocytes, thereby, playing a crucial role in
adipogenesis, lipid synthesis and in maintaining energy
balance. PPARγ activation improves insulin sensitivity.
In addition, PPARγ is expressed in spleen, large intes-
tine, white and brown adipose tissues that may account
for the involvement of these tissues in the pathobiology
of type 2 Diabetes Mellitus and metabolic syndrome [10]
[13, 14]. PPARβ is abundantly expressed in liver and ab-
dominal adipose tissues by which it regulates blood chol-
esterol, glucose levels and influences fatty acid oxidation
in cardiac and skeletal muscles [15, 16].
In the present study, we focussed on PPARγ receptor,
as it plays a critical extensive role over broad spectrum
of diseases such as type 2 diabetes mellitus, inflamma-
tory diseases, Alzheimer’s disease, and in some cancers
[17–23]. PPARγ comprises a Y-shaped ligand binding
domain (LBD), which is segmented into three arms, arm
I, arm II and arm III. Arm I is extended towards helix12
(H12), known to be polar and widely conserved across
the PPAR isoform [24–26]. It also harbors transcription
activation function-2 (AF-2) at C-terminal region and is
held in its active conformation by the hydrogen bonding
network with Arm I favouring ligand binding [27, 28].
Arm II and Arm III are found to be less conserved com-
pared to Arm I and are hydrophobic in nature [29]. It
has been proposed that diverse ligands bind to PPARγ
with different binding modes to LBD with most of the
ligand binding scenarios displaying a hydrophilic inter-
action with Arm I region and hydrophobic interactions
with either arm II or arm III regions [30].
It has been proposed that full agonists of PPARγ reside
over a large area of LBD of PPARγ with a U-shaped con-
formation and ideally comprising a polar head and a
hydrophobic tail. The polar head of the full agonist
forms a network of hydrogen bonds with the ARM-I
residues (His449, His323, Ser289, Tyr327 and Tyr473) of
PPARγ side chains. The hydrogen bonds formed with
these residues are responsible for the conformational
change of H12 and activation of PPARγ activity [31]. In
contrast, partial agonists activate PPARγ by an H12 in-
dependent mechanism, wherein, the key residues in LBD
are completely different to that of the full agonists in
that it leads to decrease in H12 stability, thereby affect-
ing the coactivators binding, which, in turn, reduces the
transcriptional activity of PPARγ [32, 33]. Most of the
previous studies suggested that partial agonists form
hydrogen bond with Ser342 of LBD [31, 33].
PPARγ agonists reduce lipid levels, enhance insulin
sensitivity and thus, show anti-diabetic and anti-
inflammatory actions. PPARγ, is well documented to be
activated by a wide range of fatty acid molecules and
their metabolites, of which PUFAs and its metabolites
play a major role in exerting beneficial effects [34].
PUFAs are also reported to play significant roles in in-
flammatory and immune responses [35], lowering the
levels of total cholesterol, Triglycerides and Low-density
lipoproteins (LDL) [36, 37], in mediating apoptosis in
colon cancer cells [38] and also shown to reduce the risk
of early atrial fibrillation during post cardiac surgery
[39]. Molecular modelling and structural bioinformatics
studies serve as powerful and efficient tools for studying
intermolecular interactions and dynamic behaviour of
molecules in an in silico simulated conditions [40–42].
In the present study, we performed molecular docking
of PPARγ against various PUFAs and its metabolites
(henceforth called as bioactive lipids) [43], keeping co-
crystal bound Rosiglitazone (BRL) as a reference struc-
ture (PDB ID: 4OF8). Further, the bound complexes
were subjected to molecular dynamics simulation to
compare the binding efficacies and to infer the agonistic
binding modes of fatty acids, which are potential thera-
peutic molecules [44, 45], towards identification of the




As a preliminary step, the crystal structure of PPARγ in
complex with Rosiglitazone (PDB ID: 4O8F) at a reso-
lution of 1.9 Å was pre-processed using Protein prepar-
ation wizard of Schrödinger suite towards optimizing
the stereochemistry by assigning proper bond order, re-
moving steric clashes, adding hydrogen atoms, fixing the
disulphide bonds, missing residues, atoms and loops.
Further refinement was performed by adjusting the ter-
minal chi rotation of Asparagine, Glutamine and Histi-
dine residues. Optimal protonation states for Histidine
residues were also assigned followed by the removal of
unwanted hetero groups. Finally, energy minimization
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was performed with OPLS2005 to obtain the optimal
geometry favourable for the commencement of plausible
docking studies.
Receptor grid generation
The receptor grid was generated using the grid gener-
ation option of the Schrodinger suite across the PPARγ
LBD domain to perform a targeted docking study. The
grid was fixed across residues that play a critical role at
the three different arms of the LBD by setting the van-
derwaals radii for the receptor with a scaling factor of
1.0 Ǻ and a partial cut off of 0.25 Ǻ.
Ligand Preparation
To expedite the protein-ligand docking workflow, all the
ligand molecules were optimized using Schrodinger Lig-
prep module by fixing the vanderwaals radii with the scal-
ing factor of 0.80 Ǻ and a partial charge cut-off of 0.15 Ǻ.
Finally, the optimized compounds were energy minimized
with OPLS 2005 as force field.
Receptor- Ligand Docking
Docking studies establish interactions between protein
and ligand molecules, thereby, aids in identifying the
most favourable binding pose forming a stable complex
with significant binding affinity, as scored by the docking
score [46]. In this study, protein-ligand docking was per-
formed using Schrodinger Glide version [7.0] across the
grid set over the LBD region. Here, a flexible docking
was performed against 10 ligand molecules, in which the
best binding pose among 100 generated poses for each
molecule was determined based on the Glide XP dock-
ing score. A rigid Re-docking was also performed for the
rosiglitazone (BRL) against its bound crystal structure by
setting the grid across the LBD so as to infer the predict-
ive efficacy.
MMGBSA Scoring
Molecular Mechanics Generalized Born Surface Area
(MMGBSA) scoring was also performed for all the
docked complexes to calculate the binding free energies
by implementing the equation through Schrödinger
Prime Module:
ΔGGB ¼ ΔEMM þ ΔGsolv þ ΔGSA
Where electrostatic solvation energy (ΔGGB) was cal-
culated by using the GB Models, ΔEMM is the difference
between the minimized energies of ligand-protein com-
plex and the total energies of protein and ligand in free
form. ΔGsolv is the difference in the GBSA solvation en-
ergies of the ligand-receptor complex and the sum of
the solvation energies of receptor and ligand in the un-
bound state. ΔGSA is the difference in the surface area
energies for the free receptor and the ligand. It is used
to identify plausible binding conformations among the
docked complexes in terms of binding free energy to-
wards further stringent ranking of the complexes [47].
Molecular Dynamics simulation
Molecular dynamics simulation was performed for apo,
co-crystal structure (PDB id: 4O8F) and for all the
Fig. 1 Schematic representation of in silico study on PPARγ agonists. (Note: PUFA molecule and its metabolites are collectively referred as
bioactive lipids)
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docked complexes using Desmond 3.6. The system was
built using a cubical box solvated with Simple Point Charge
(SPC) water model. Subsequently, the system was neutral-
ized by adding 4 Na+ ions for apo and 5Na+ ions for com-
plexes at a concentration of ~6.22 mM. Further, this system
was energy minimized with OPLS2005 as force field [48].
SHAKE algorithm was applied to restrain the geometry of
water molecules, bond lengths and angles of heavy atoms
and to constrain covalent bonds during MD simulation
[49]. Periodic Boundary Conditions (PBC) were applied to
stimulate a continuous system [50] and Particle Mesh
Ewald method (PME) was applied for long range electro-
statics [51]. Further, the system was equilibrated with NPT
ensemble by setting temperature and pressure parameter to
300 K and 1.0 Bar, respectively. Nose-Hoover chain and
Martyna-Tobias-Klein was chosen as a coupling algorithm
for temperature and pressure, respectively [52, 53]. Further,
the equilibrated system with a total of 48,294 atoms was
simulated for 20 ns (nanosecond) with a time step of 2 fs
(femtosecond) and trajectories were recorded after every
1.0 ps. The Root Mean Square Deviation (RMSD) was cal-
culated for the backbone atoms and were graphically
analysed at a time point scale [54, 55]. Similarly, root
mean square fluctuation (RMSF) for each residue was also
calculated to compare the major conformational changes
in the residues between apo form and docked complex
forms by keeping the rosiglitazone (BRL) bound crystal
structure as a reference [56]. The radius of gyration was
also calculated to infer the compactness of protein-ligand
complexes for the comparison with apo form [57]. The
2D inter-molecular interaction plots depicting the com-
plex stability during the MD run was also generated to
infer the stability of all the complex structures.
Results
Comparative Molecular Docking studies of PPARγ with
bioactive lipids
Molecular Docking was performed for all the 10 bio-
active lipid compounds against the PPARγ-LBD. Glide
XP dock score and MMGBSA binding free energy score
were calculated for all receptor-ligand docked com-
plexes, which revealed the scores to be in the range of
−4.8 to −9.9 kcal/mol and −71.147 to −106.046 kcal/mol
(Table 1), respectively. Further, 2D interaction maps with















Resolvin E1 (RsvE1) −9.900 Hie449:NH REV1: O −106.046
Tyr327:HO REV1: HO
Glu291: O REV1: HO
Neuroprotectin D1 (NPD1) −9.664 Ser289:OH NPD1: O− −102.57
Ser289:OH NPD1: OH
Hydroxy-linoleic acid (H-LA) −6.235 Tyr473:OH HLA:HO −95.027
Ser289:OH HLA: O−
Docosahexaenoic acid (DHA) −7.925 Hie323:NH AA: O −89.785
Lipoxin A4 (LXA4) −5.796 Tyr327:OH LXA4: HO −87.547
Hie449:NH LXA4: O
Gamma-linoleic acid (GLA) −5.068 Hie323:NH GLA: O− −77.117
Ser289:OH GLA: O−
Arachidonic acid (AA) −7.040 Hie323:NH AA: O −76.586
Alpha-linoleic acid (AL) −5.174 Hie449:NH AL: O− −73.657
Eicosapentaenoic acid (EPA) −7.126 Hie323:NH EPA: O −71.147
Ser289:OH EPA: O
Linoleic acid (LA) −4.820 Glu343:NH LA: O− −78.026
Compounds are ranked collectively based on XP glide score and MMGBSA score showing significance with reference ligand
rosiglitazone (RsvE1 > NPD1 > HLA > DHA > LXA4 > GLA > AA > ALA > EPA > LA)
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a cut-off of 4 Å for each docked complex was generated
to visualize the intermolecular interactions. This inferred
that all the compounds to be majorly stabilized by
hydrogen bonds during complex formation (Fig. 2). The
re-docking of Rosiglitazone to PPARγ-LBD also showed
an agreeable deviation of 0.4 Å, inferring the predictive
accuracy. The 2D maps were further scrutinized for lig-
and contacts with the hotspot residues spanning Arm-I,
Arm-II, Arm-III and AF-2 domain towards classifying
potential full and partial agonists.
Molecular dynamics simulation of the docked complexes
An unrestrained molecular dynamics simulation study of
apo form and all docked complexes were performed to
infer the backbone stability, residue fluctuations, struc-
tural compactness measured in terms of RMSD, RMSF,
and Rg, respectively. The RMSD trajectory revealed that
all complexes to be stable during the entire production
run with the system convergence at ~15 ns (Fig. 4). The
RMSF trajectory inferred maximum fluctuations at L1
(238–251) and L2 (260–276) regions across all the apo
and docked complexes (Fig. 5a). Rg trajectory also re-
vealed structural compactness in apo and protein-ligand
complexes (deviation within 1 Å) (Fig. 5b). A trajectory
of Intra-molecular hydrogen bond counts (mean average
of 210 H-bonds) was plotted for the entire production
run. As expected, there was a gain in h-bonds in docked
complexes in comparison with holo forms (Fig. 5c). For
Fig. 2 2D ligplot interaction diagram of all the 10 docked bioactive lipids complexed with PPARγ and re-docked rosiglitazone. a Rosiglitazone b Resolvin E1
c Neuroprotectin D1 d Hydroxylinoleicacid e Docosahexaenoicacid f LipoxinA4 g Gammalinoleicacid h Arachidonicacid i Alphalinoleicacid j Eicosapentaenoic
acid k Linoleic acid
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the top three ranking hits, Protein-ligands contact bar
charts were plotted, which inferred the contribution
of hotspot residues in establishment of intermolecular




Molecular Docking studies were subsequently performed
for all the bioactive lipids against the assigned grid sur-
face on the protein. The docked complexes were ana-
lysed for the Glide XP score, MMGBSA score and H-
bond interactions, to collectively infer the ligand binding
affinity [58, 59]. The Glide receptor-ligand docking re-
sults are tabulated in (Table 1). Among the docked com-
plexes, Resolvin E1 (RsvE1), neuroprotectin D1 (NPD1)
and hydroxy-linoleic acid (H-LA) showed significant affin-
ity compared to other compounds in terms of XP dock
score of −9.900 kcal/mol, −9.664 kcal/mol and
−6.235 kcal/mol, along with a relative MMGBSA score of
−106.046 kcal/mol, −102.57 kcal/mol and −95.027 kcal/
mol, respectively. RsvE1 displayed strong intermolecular
interactions, by forming three H-bonds with the key side
chain amino acids of LBD: amino group of Hie449 (H11),
hydroxyl group of Tyr327 and Oxyl group of Glu291.
NPD1 showed two H-bonds with the side chain of Ser289
and H-LA formed two H-bond interactions with the OH
group of side chain amino acids Tyr473 (H12) and Ser289
(H3), respectively. Moreover, RsvE1, NPD1 and H-LA also
showed a significant scoring comparable to that of the ref-
erence ligand rosiglitazone (BRL), both in terms of
docking score as well as MMGBSA score. Rosiglitazone
on re-docking with the crystal structure yielded a XP dock
score of −6.833 kcal/mol and MMGBSA score of
−105.038 kcal/mol. The glide re-docked complex of rosi-
glitazone (BRL) showed a RMSD of 0.446 Ǻ on structural
alignment with the native PPARγ-Rosiglitazone co-
crystallized structure, inferring the predictive accuracy of
the method implemented (Table 1).
RsvE1, NPD1 and H-LA formed hydrogen bonds with
the arm-I residues Hie449 (H11), Ser289(H3) and
Tyr327, which are reported to be important for produ-
cing full activity of the compound by direct stabilization
of H12 helix and are responsible for the transactivation
activity of PPARγ [24, 31, 60, 61]. HLA also formed a
hydrogen bond with Tyr473 (H12) located on the arm I
that harbours transcription activation function-2(AF-2),
which is obligatory for ligand binding and as well as in
complimenting PPARγ function [27]. Tyr473 is also hy-
pothesized to play a crucial role in AF-2 stabilization, as
it occupies helix12 which closes the ligand binding site
upon ligand binding. This activity of helix12 favours in
the reduction of conformational fluctuations that sets an
optimal LBD structure for co-activator binding. It has
also been reported that mutation at Tyr473 leading to
the loss of agonistic activation by the ligands.
Alpha-linoleic acid (ALA) showed a Glide XP dock
score of −5.174 kcal/mol by forming a single H-bond
with the side chain of Hie449 (H11). Arachidonic acid
(AA) and docosahexaenoic acid (DHA) formed a single
H-bond with the side chain of Hie323 with an XP dock
score of −7.040 kcal/mol and −7.925 kcal/mol,
Fig. 3 All the 10 bioactive lipids were found to be docked within the three arms of the Ligand Binding Domain (LBD). All the ligands are
represented as sticks with different colours (BRL: red, RsvE1: green, NPD1: sky blue, H-LA: pale green, DHA: light blue, LXA4: sand, GLA: orange, AA:
pale yellow, AL: wheat, EPA: light pink, LA: aquamarine). ARM I (orange) involving four key residues (Tyr473, His323, His449, Ser289 and Tyr327) and
AF-2 at the C-terminal end of LBD critical for co-activator binding pocket. ARM II (magenta) constitutes six residues (Met364, Ile281, Met348, Ile341
and Lys367) and ARM III (blue) with (Ala292, Leu333 & Ser342)
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respectively. Eicosapentaenoic acid (EPA) and gamma-
linoleic acid (GLA) displayed a XP dock score of
−7.126 kcal/mol and −5.068 kcal/mol by forming two
hydrogen bonds with the side chain residues of Hie323
and Ser289, respectively. Lipoxin A4 (LXA4) with a
docking XP score of −5.796 kcal/mol, displayed two
hydrogen bond interactions with the active site residues
Hie 449 and Tyr327. Linoleic acid (LA) showed the least
XP dock score of −4.820 kcal/mol among all the docked
bioactive lipids compounds by forming an H-bond with
the back bone of Glu342 (Table 1).
The ligand interactions with ARM-I side chains of
Hie323 (H3), Hie449 (H11), Ser289(H3) and Tyr327
of LBD is reported to play a significant role in en-
hancing agonistic activity as it is found to indirectly
influence the H12 stabilization [24, 31, 60, 61]. Of
the 10 docked complexes, 9 bioactive lipids are pre-
dicted to act as full agonists for PPARγ by forming
an H-bond interaction with the ARM-I hydrophilic
cavity residues (Hie 323, Hie 449, Tyr473, Ser289
and Tyr327). Linoleicacid has been found to be a
partial agonist for PPARγ as it formed H-bond inter-
actions with Glu343 of ARM-III [24]. The superim-
position of all ten ligand molecules (bioactive lipids
studied in the present study) along with the rosigli-
tazone as a reference ligand, inferred all the ligands
to be well bound within the three arms of agonist
binding domain by interacting with key residues
(Figs. 2 and 3) [32, 62].
Molecular dynamics studies of the protein-ligand
complexes
The RMSD trajectory of the backbone atoms of apo
form and all the complex structures showed a conver-
gence after a time frame ranging from ~ 13,000 ps to ~
15,000 ps with a maximum mean value of ~3.5Ǻ and
S.D of 0.675Ǻ (Fig. 4). The RMSF fluctuation has
reached the maximum peak limit of 6-7Ǻ at the residues
residing over the lengthy loop region (Loop1 with 14
residues and Loop2 with 17 residues) and remaining
Fig. 4 RMSD graph showing the backbone atoms convergence of all the complex structures
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Fig. 5 a RMSF graph displaying major fluctuations at the two lengthy loop segments L1 and L2 and Helix 12 (H12) in all the holo forms showing
a less fluctuation than the apo form. b Radius of gyration graph staging the compactness of the protein-ligand complexes and c Intra-molecular
H-bonds showcasing no major loss in the protein complex secondary structures
Fig. 6 a-c Protein-ligand contact of RsvE1, NDP1 and H-LA with PPARγ showing strong intermolecular interactions with the key active site residues
over the period of simulation 20 ns
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residues showed fluctuations within 1Ǻ. The H12
(Tyr473) residue showed a slightly higher fluctuation in
the apo form compared to all the other protein-ligand
complexes. This corroborates with the hypothesis that
upon ligand binding to H12 hotspot to confer closure of
LBD, thereby stabilizes the LBD conformation in the lig-
and bound state (Fig. 5a) [27]. The apo form and all the
10 (bioactive lipids) complexes were found to be com-
pact; by displaying a radius of gyration less than ~ 1.3
(Fig. 5b). The intra-molecular H-bond graph also in-
ferred no major loss in the protein secondary structure
conformations, thereby, reinforcing that the protein-
ligand complex structures to be well stabilized (Fig. 5c).
However, the protein complexed with the ligands Rsv
E1, NPD1 and H-LA were found to establish strong
protein-ligand contacts by constituting plausible inter-
molecular H-bonds with the active site residues of the
LBD domain throughout the period of simulation.
RsvE1, NPD1 and H-LA displayed a consistent and
plausible H-bond interactions with the critical residues
of ARM-1 (Hie323, Tyr327, Hie449, Lys367 and Tyr473)
for ~50% during the production run (Fig. 6a-c). The
three bioactive lipids (RsvE1, NDP1 and H-LA) interact-
ing with two conserved side chain amino acids Tyr327
and Lys367, are reported for favouring the formation of
H-bonds at the Keto-group of the ligands. These amino
acid side chains are known to play a vital role in deter-
mining the specificity of ligands that can efficiently
couple with the receptor [62] (Fig. 6a and b). It is note-
worthy that these residues of arm-1 (His323, His449,
Tyr473, Tyr327 and Lys367) are hypothesized for indir-
ect and direct stabilisation of H12 (Tyr473), thereby
favouring for co-activator binding and for contributing
towards the transactivity of PPARγ.
Conclusion
In the present study, we performed a molecular docking
analysis with bioactive lipid compounds which are docu-
mented to be agonists of PPARγ [30]. All the 10 docked
complexes were found to be well bound within the three
different arms of LDB. Thereby in-order to perform a
further comparative study on the protein-ligand inter-
action stability and the conformational stability of the
LBD, molecular dynamics studies were carried out for
apo form, LBD co-crystallized with rosiglitazone and for
all the docked complexes with bioactive lipids.
The cumulative analysis based on the Glide score,
Prime-MMGBSA free binding energy score and MD tra-
jectories analysis infer that RsvE1, NDP1 and H-LA to
be the best docked compounds as these three showed
relatively a significant score to that of the re-docking
score of the reference ligand Rosiglitazone in terms of
glide XP score, MMGBSA score and H-bond forming
pattern with the key residues (Table 1). The MD
trajectory also reinforce that RsvE1, NDP1 and H-LA to
be the best compounds based upon the RMSF graph
(Fig. 5a), which clearly depicts that upon RsvE1, NDP1
and H-LA ligands binding to the LBD, it displays a
much lesser fluctuation at H12 region in comparison to
that of the reference ligand Rosiglitazone (BRL) and
thereby maintaining a stable LBD structure for co-
activator binding.
The protein-ligand contacts of the RsvE1, NDP1 and
H-LA with PPARγ throughout the production run of
20 ns also corroborates well by displaying a strong inter-
molecular interaction with the key active site residues of
the LBD domain over ~50% of the simulation time,
which confirms the stability upon the ligand binding and
its intactness with the receptor.
Moreover, RsvE1 is found to mimic the insulin sensitizing
and anti-steatotic activities of omega-3-PUFAs, and also
found to induce adiponectin expression similar to rosiglita-
zone [63]. NPD1 interacting with the PPARγ is
hypothesized to be play a significant role in suppressing
neuroinflammation and thus, is considered to be of benefit
in some neurodegenerative diseases [64]. Hydroxy-linoleic
acid (H-LA) is reported to have anti-proliferative action on
tumor cells [65]. In the present study, we have ranked all
these PUFA compounds collectively based on the Glide
docking score, H-bonding formation with the key residues,
Prime MMGBSA score and MD simulation trajectory ana-
lyses and observed that their relative PPARγ agonist activity
to be as follows: RsvE1 >NPD1 >H-LA >DHA >LXA4 >
GLA >AA>ALA> EPA > LA. However, Further experi-
mental studies need to be performed to verify the results
obtained in the present bioinformatics analysis. Such stud-
ies could include the assessment of ability of these bioactive
lipids in the pathobiology of obesity, insulin resistance, type
2 DM, metabolic syndromes and cancer.
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